Aim: Continued smoking in patients diagnosed with cancer affects treatment outcomes and overall survival. With national surveys of Australian medical oncologists (MO) and radiation oncologists (RO) we sought to determine current clinical practices, preferences and barriers in providing patient smoking cessation support.
INTRODUCTION
The optimal care of people diagnosed with cancer includes all measures known to improve their long-term cancer outcomes and to reduce the development of new diseases. 1 Within the Asia-Pacific, at least 14% of patients with cancer are current smokers at the time of diagnosis, 2 with the reported range as high as 64% for some cancer types. 3 This sizeable subgroup suffers greater toxicity and higher hospitalization rates during cancer treatment, 4-8 a greater likelihood of cancer recurrence and lower cancer and overall survival rates. [9] [10] [11] [12] [13] Not surprisingly these effects equate to significantly different estimated survival probabilities for continuing smokers versus recent quitters (<12 months) diagnosed with cancer in Australia; 37 vs 43% respectively at 8 years postdiagnosis. 14 Such survival differences are comparable with the gains from cancer screening programs and adjuvant therapies.
Accordingly addressing smoking in patients with cancer is a focus of international clinical and research efforts. In 2014, the US Surgeon General stated that in this patient group "smoking status is a powerful clinical risk indicator that merits the full attention of the health care team and the patient." 15 The American Society of Clinical Oncology (ASCO) endorses addressing patient tobacco use at diagnosis and throughout treatment, and the applicability of the "Five As" method of tobacco cessation 16 to the cancer care setting. 17 In 2015, the National Comprehensive Cancer Network issued their first clinical guidelines for smoking cessation, recommending cessation support as a universal component of the treatment plan for patients with cancer that smoke. 18 From the patient perspective, smokers diagnosed with cancer are often motivated to attempt quitting, and are more likely to succeed than those in the general population. 19, 20 The limited existing data suggest that there is suboptimal implementation of smoking cessation support in clinical oncology, however. In 2012, a survey of ASCO members found that almost all believe smoking affects patient outcomes, and most routinely assess patient smoking status, yet the minority actively provide cessation assistance. 21 A more recent survey of multidisciplinary oncology staff working in hospitals within New South Wales, Australia, found that less than 30% consistently provide cessation support to smokers. 29 We sought to obtain comprehensive updated information on the smoking cessation practices of oncologists in the first national surveys of Australian medical oncologists (MO) and radiation oncologists (RO).
We also aimed to document practitioner self-assessed training levels, beliefs, and preferences in the provision of smoking cessation care. As the central health care providers for patients with cancer, such data are critical to informing the future design of effective strategies targeting this evidence-practice gap in cancer care.
METHODS

National surveys
Australian MO and RO were invited to participate in a brief survey (Supporting Information) modified from that of Warren et al, 30 exploring smoking cessation practices and beliefs. Surveys were distributed by the peak representative groups for each discipline; the Medical Oncology Group of Australia (MOGA) and Trans Tasman Radiation Oncology Group (TROG) to all fully qualified oncologist members. Surveys were distributed in paper by post and included reply paid envelopes for return to the study team. The respective surveys were identical other than minor discipline-specific terminologies for doctors in training, and completion of each was incentivised with a retail voucher prize draw. 
Data analysis
Responses to the MOGA and TROG surveys were collated separately and then combined into a single file. 
RESULTS
Survey participants
Smoking cessation practices
Current care provided
The surveys recorded oncologist assessment of the patient's smoking status and subsequent actions at initial and at follow-up consultations. During initial patient consultations, more than 90% of both MO and RO always, or most of the time, asked patients if they smoked or used tobacco products (Table 1) . For patients who smoked, the duration of their smoking history and current level of consumption was recorded by 89-96% of MO and RO either always or most of the time ("regularly"). After recording these details of the patient's smoking history, a proportion of oncologists took no further action. Among MO, 63% regularly asked patients if they were intending to quit, and 70% advised cessation. For RO, these results were 53% and 72%,
TA B L E 1 Frequency of oncologist actions at an initial patient consultation
Never / rarely Some of the time Most of the time / always
MO (%) RO (%) Pooled (%) MO (%) RO (%) Pooled (%) MO (%) RO (%) Pooled (%)
Ask your patients if they smoke or use tobacco products 
respectively. Less than one-fifth of oncologists from either discipline regularly discussed medication options to assist in cessation (17% MO, 15% RO), and active management of the patient's smoking cessation was regularly performed by only 2% of MO and 3% of RO. Rates of referral to a tobacco cessation support program (e.g. Quitline) were higher, with 15% of MO and 22% of RO always or mostly referring patients, followed by regular referrals to a cessation specialist (7% of MO and 18% of RO, P = 0.003). Brochures were seldom used by either discipline (3% of MO, 6% of RO).
During follow-up consultations, 39% of MO and 44% of RO regularly asked about current smoking or tobacco use ( Table 2 ). The importance of stopping tobacco use was regularly reinforced by just over half of all oncologists (50% MO, 57% RO). The proportion of oncologists taking action to support smoking cessation during follow-up consultations (actively treating, referral to a support program or cessation specialist) was the same or lower than the proportion regularly taking these actions at initial patient consultations (Tables 1 and 2 ).
Target patient groups
Oncologists were asked which patient subsets they would regularly provide smoking cessation assistance to. Patients suffering tobaccorelated cancers were most likely to be offered assistance (by 48% of MO, 62% RO; Table 3 ). A minority of oncologists would provide assistance to only those patients with curable malignancy (24% MO, 34% RO), and a similar proportion would not provide assistance to any patients (23% MO, 27% RO). Medical oncologists were significantly more likely to offer assistance to all patients, including those with metastatic disease (41%), than were RO (15%; P < 0.001). Free text comments (Supporting Information) entered in response to this question mentioned consideration of life expectancy in patients with metastatic disease, offering assistance only to those patients who request it, the provision of advice but not assistance, and referral to the patient's General Practitioner (primary care physician) for the cessation support.
Preferences: how and when
Assuming all listed options were available, oncologists were asked to nominate one or more methods of smoking cessation assistance they would prefer to use regularly. Both disciplines most preferred use of a service run by trained workers at their own institution (61% MO, 71% RO) or referral to the patients' General Practitioner (69% MO, 61% RO) ( Preferred times to provide smoking cessation assistance were at the initial patient consultation (57% MO, 67% RO) or after completion of cancer treatment (53% MO, 50% RO). Less than half of oncologists would also provide assistance during cancer treatment (44% MO, 33% RO). Some allowed the timing to be dictated by the service to which the patient had been referred (36% MO, 39% RO). 
TA B L E 2
Frequency of oncologist actions at follow-up consultations for patients with a history of tobacco use Never / rarely
Smoking cessation beliefs 3.3.1 Relevance, roles and concerns
Beliefs regarding the importance of smoking cessation in patients with cancer and potential concerns about the institution of cessation support were investigated with a series of statements allowing participants to respond with the strength of their agreement. Results are shown in Figure 1 . The large majority (94%) of oncologists agree that current smoking impacts cancer treatment outcomes, although RO showed greater conviction than MO (strongly agree: MO 37%, RO 64%, P < 0.001). The majority (87%) also agreed that tobacco cessation should represent a standard component of cancer treatment (MO 87%, RO 88%). Both disciplines agreed that each member of the oncology team (medical, nursing, allied health) should have a role in supporting smokers to quit (MO 75%, RO 70%).
With regard to training, the majority of oncologists disagreed with the statement "I have had adequate training in tobacco cessation interventions'' (MO 68%, RO 70%), with most of the remaining selecting a neutral response (Figure 1 ). Only 3% of MO and 1% of RO strongly agreed that they had received adequate training. In line with these responses, the majority believed they require more training in cessation interventions (67% MO, 57% RO) and that trainees in their discipline would benefit from greater training (75% MO, 67% RO).
Oncologists were questioned about possible concerns regarding smoking cessation during cancer treatment. Most MO (64%) and RO (67%) agreed that they did not know enough about potential interactions between cessation pharmacotherapies and cancer treatments or supportive drugs. Responses regarding concern about the impact of smoking cessation on patients' ability to manage their cancer treatment were more varied (Figure 1 ).
Barriers to care
Perceived barriers to providing smoking cessation intervention were investigated ( Figure 2 ). Results were similar for MO and RO. Most oncologists agreed with all the potential barriers suggested other than that smoking cessation was a waste of time, to which the majority disagreed (85% MO, 88% RO), with RO showing the strongest conviction (33% MO strongly disagreed, 50% RO, P = 0.004).
Developing expertise
Oncologists were asked the level of smoking care expertise they believed they should possess. The majority felt that basic skills were and professional society guidelines (48% MO, 38% RO).
Oncologist feedback
In addition to free text comments to individual questions, the final survey question consisted of an invitation to the oncologist to make any further comment they wished. Lengthy comments were entered by 18% of oncologists and are included in the Supporting Information.
DISCUSSION
We present the first national surveys of Australian medical and radia- similarly documented a lack of specific action in aiding smoking cessation despite identifying the patient as a smoker. 31, 32 The most stark clinical practice finding was the strong preference of oncologists for smoking cessation care to be managed by other health workers, with only 4% of MO and 0% of RO preferring to manage the cessation care themselves. Oncologist-perceived barriers to providing smoking cessation interventions spanned nihilism about their ability to convince patients to quit, patient resistance and a lack of time, training and resources-all nominated by more than 50% of MO and RO.
Free text responses additionally mentioned that the number of issues to cover in a patient consultation (regarding the cancer diagnosis and its treatment) already approached "overload" for the patient and/or oncologist, precluding adding smoking cessation as an additional topic of discussion. The benefits of smoking cessation in patients with advanced cancer and a limited prognosis require more specific study.
Although the 43% response rate to this national survey is substantially higher than the survey of ASCO members (6%), 21 there is nonetheless the potential for bias related to the participating subgroup, with those most interested in smoking cessation possibly more likely to participate. An additional limitation of the survey is the self-report nature of the findings given that physicians have been previously shown to overestimate their provision of smoking cessation care. 29, 30 The use of medical consultation notes to verify the care provided is problematic, however, due to the significant underdocumentation of smoking care in medical records. 29, 31 Other methods utilized to measure the prevalence of cessation care include patient interview and direct observation of consultations 32 ; however, the former may also over-report the care received 29 and there is currently no accepted "gold standard" measurement tool. Although the survey assessed oncologists' perceived levels of training in smoking cessation care, and their beliefs regarding the need for further education, it did not explicitly measure oncologists' knowledge of cessation interventions or professional guidelines and hence levels of ability are unknown.
This survey addressed oncologist views and practices regarding current smokers, but not recent quitters and the prevention of smoking relapse. Despite the motivation of many smokers diagnosed with cancer to quit, 19, 20 relapse rates are high. 33 The provision of ongoing cessation care to recent quitters is likely to be poorer than that to current smokers as limited data suggests that oncologist-initiated discussion of smoking ceases once the patient reports having quit. 24 This misses the opportunity to identify and assist patients whom initially abstain but later relapse, and those who may actually still be smoking when they report having quit (especially given that biochemical testing in patients with cancer has been shown to vary significantly from self-reported smoking status 34, 35 ).
The evidence-practice gap in smoking cessation care in oncology is large. The results of this survey provide critical information with regard to current oncologist practice and, most importantly, oncologist preferences. As the central healthcare providers for patients with cancer, it is essential that oncologists are actively engaged with implementation strategies for improved smoking care. Our results show that although oncologists believe that smoking impacts cancer treatment outcomes and that smoking cessation care should be routine, they do not wish to manage the cessation care themselves. In light of this finding, we suggest a team approach to cessation care where oncologists may be the first to engage with the patient regarding the need for cessation, providing for example; brief motivational advice with information about the individualised benefits of quitting, and formulation of an agreed plan with the patient on the most appropriate referral and support strategy. This should be followed by engagement with adequately resourced, accessible health professionals who understand both cancer treatment and smoking cessation. 26 Multiple practice models could be developed to meet these requirements. Follow-up on the patient's progress by the oncologist would provide continuity and may aid in preventing relapse. 
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